Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
34 papers
This study reviewed systematic reviews to measure death risks in major mental disorders. The authors screened 407 reviews and found 20 that reported mortality risks for 20 different disorders, covering over 1.7 million patients and more than a quarter of a million deaths. Every disorder showed higher all-cause death rates…
Borderline personality disorder (BPD) is a serious mental illness marked by big problems with emotion control, impulsive acts, and unstable self-image and relationships. Many people with BPD hurt themselves or try suicide (recurrent suicidal behaviour in about 69–80% and suicide rates up to 10%). Mentalization-based treatment (MBT) was developed to…
The authors combined results from 42 studies of people in prison to estimate how common ADHD is in those groups. Using formal diagnostic interviews, the overall ADHD rate was about 25.5%. Reported rates were higher when studies used screening tools or when adults recalled childhood ADHD. The review found much…
This paper reviews genetic studies that link several genes to higher risk for ADHD. It says problems in the brain's reward system—especially low dopamine activity—may make people seek things that raise dopamine. The authors propose that these gene variants form a “reward deficiency syndrome” (RDS) that may include ADHD, and…
Researchers reviewed records from 1,130 people with bipolar disorder seen at a mood-disorders center. They found that depressive episodes lasted much longer than manic episodes, and that episode length was similar across bipolar subtypes (BD-I, BD-II, mixed, or with psychosis). The authors say this pattern — more and longer depressions…
This small pilot randomized placebo‑controlled trial tested a cannabinoid spray (Sativex) in 30 adults with ADHD. The main test of cognition and activity (QbTest) showed no significant difference between Sativex and placebo in the intention‑to‑treat analysis (Estimate = -0.17, 95% CI -0.40 to 0.07, p = 0.16). Some secondary measures…
Sleep problems are very common in bipolar disorder, which affects about 1% of people in their lifetime. Research suggests these problems relate to disruptions in both the body’s internal clock (circadian system, “process C”) and the sleep–wake drive (homeostasis, “process S”), though this is not proven to be the single…
This systematic review looked at human studies of cannabidiol (CBD) for anxiety up to June 2019. Eight studies were included (6 small randomized controlled trials, 1 case series, and 1 case report). The studies tested CBD for anxiety in healthy volunteers, generalized anxiety disorder, social anxiety disorder, and PTSD-related anxiety.…
Most of the included studies were at high risk of bias and the overall quality of the evidence ranged from low to very low on most outcomes. Although amphetamines seem efficacious at reducing the core symptoms of ADHD in the short term, they were associated with a number of adverse…
Attention-deficit/hyperactivity disorder (ADHD) is a prevalent and serious neurodevelopmental disorder characterized by symptoms of inattention and/or hyperactivity/impulsivity. Chronic and childhood stress is involved in ADHD development, and ADHD is highly comorbid with anxiety. Similarly, inflammatory diseases and a pro-inflammatory state have been associated with ADHD. However, while several works have…
This 2017 clinical review explains how bipolar I and II disorders are diagnosed and treated. It says bipolar illness involves swings between manic (or hypomanic) and depressive episodes. Treatment usually needs both medicines and psychosocial therapy, and care must be adjusted over time because relapses and incomplete responses — especially…
This review looked at 14 clinical papers about esketamine for adults whose depression did not get better after usual treatment. It found that most studies support using esketamine as an add-on to standard antidepressants for treatment‑resistant depression, but the evidence about long‑term benefit and safety is limited. Some trials did…
